New product launches and FDA win offset cut to sales growth outlook
Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.